Human Genome Sciences
Executive Summary
Pulmozyme (DNase) cystic fibrosis treatment marketer Genentech receives exclusive option to license the heart/lung selective DNase (HL-DNase) gene from Rockville, Md.-based gene sequencing company. The agreement, announced April 20, "represents the first example of HGS initiating commercial development of a technology" that has been released by its development partner SmithKline Beecham. SB will share "any proceeds" from the Genentech agreement
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth